Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Eclipse Bio Expanding Assay Portfolio, Moving Into RNA Modification Research

Eclipse Bio Expanding Assay Portfolio, Moving Into RNA Modification Research

Aug 20, 2020
|
Adam Bonislawski
Premium

NEW YORK – RNA research firm Eclipse Bioinnovations is working to expand its assay portfolio and drive adoption of its eCLIP method for studying RNA-protein binding.

The company is also increasing its capabilities around analyzing modified forms of RNA, which is an area of growing interest among cancer drug developers, said Gene Yeo, professor of cellular and molecular medicine at the University of California, San Diego and developer of the eCLIP technique.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

P.1 Re-infection Concerns

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

Aiming for May

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

NIH Program to Address Structural Racism

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

PNAS Papers on Myelopathy GWAS in Japan, Hypertrophic Cardiomyopathy, MRSA Methylation

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.

Mar
09
Featured Webinar

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

Sponsored by
Fabric Genomics

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams. 

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

What's Popular?

In Sequencing

  1. Twist Bioscience, Watchmaker Genomics Partner on High-Throughput NGS Applications

  2. Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service

  3. TGen-Led Team Spots Pediatric, Pancreatic Cancer From cfDNA Fragments in Urine

    Premium

  4. Strata Oncology, Pfizer Partner to Explore New Biomarker Indications for FDA-Approved Drugs

  5. New Method Provides NGS-Based Readout of Glycan Levels in Single Cells

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.